Document

S-8 1 s-82014planregistrationfeb.htm S-8 Document

As filed with the Securities and Exchange Commission on February 26, 2026

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM S-8

REGISTRATION STATEMENT UNDER THE

SECURITIES ACT OF 1933

______________________

PACIRA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)


Delaware			51-0619477
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)

2000 Sierra Point Parkway, Suite 900 Brisbane, California 94005
(Address and zip code of principal executive offices)

Pacira BioSciences, Inc. Amended and Restated 2014 Inducement Plan
(Full title of the plan)

Frank D. Lee

Chief Executive Officer

Pacira BioSciences, Inc.

2000 Sierra Point Parkway, Suite 900

Brisbane, California 94005

(Name and address of agent for service)

(650) 242-8052

(Telephone number, including area code, of agent for service)

______________________
Copy to:

Jason Day

Ned A. Prusse

Jonathan S. Schulman

Perkins Coie LLP

1900 Sixteenth Street, Suite 1400

Denver, Colorado 80202

(303) 291-2300

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o

EXPLANATORY NOTE

Pacira BioSciences, Inc. previously filed Registration Statements on Form S-8 with the United States Securities and Exchange Commission (the “SEC”) on June 5, 2014 (File No. 333-196542), February 29, 2024 (File No. 333-277556), and February 27, 2025 (File No. 333-285365) (collectively, the “Prior Registration Statements”), pertaining to, among other things, the registration of an aggregate of 2,310,000 shares of common stock, par value $0.001 per share (the “Common Stock”), authorized to be issued pursuant to the Pacira BioSciences, Inc. Amended and Restated 2014 Inducement Plan (as amended and restated to date, the “Plan”). The registrant hereby incorporates by reference the contents of the Prior Registration Statements to the extent not otherwise amended or superseded by the contents of this Registration Statement.

This Registration Statement is being filed pursuant to General Instruction E of Form S-8 to register under the Securities Act of 1933, as amended, the offer and sale of an additional 750,000 shares of Common Stock pursuant to the Plan. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the Plan, are incorporated herein by reference and made part of this Registration Statement, except as amended, supplemented, or superseded hereby.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents filed by the registrant with the SEC are hereby incorporated by reference in this registration statement:

(1)The registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026;

(2)The registrant’s Current Reports on Form 8-K filed with the SEC on January 28 , 2026;

(3)The description of the registrant’s common stock contained in the registrant’s Registration Statement on Form 8-A filed with the SEC on January 28, 2011 under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendments or reports filed for the purpose of updating such description (including Exhibit 4.3 to the registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on February 21, 2020).

All documents filed by the registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date hereof, and prior to the filing of a post-effective amendment that indicates that all the securities offered hereby have been sold or that deregisters the securities offered hereby then remaining unsold, shall also be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference in this registration statement.

Any statement contained in this registration statement or in a document incorporated or deemed to be incorporated by reference in this registration statement will be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this registration statement modifies or supersedes that statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

Item 8. Exhibits.


Exhibit No.			Description
5.1			Opinion of Perkins Coie LLP.
23.1			Consent of KPMG LLP.
23.2			Consent of Perkins Coie LLP (included in Exhibit 5.1).
24.1			Power of Attorney (see signature page of this Registration Statement).
99.1			Pacira BioSciences, Inc. Amended and Restated 2014 Inducement Plan (incorporated by reference to Exhibit 10.7 to the registrant’s Annual Report on Form 10‑K filed on February 26, 2026).
107			Filing Fee Table.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Brisbane, State of California, on February 26, 2026.


						PACIRA BIOSCIENCES, INC.
						/s/ FRANK D. LEE
						Frank D. Lee Chief Executive Officer and Director

POWER OF ATTORNEY

Each person whose individual signature appears below hereby authorizes Frank D. Lee, Shawn M. Cross, and Kristen Williams, or any of them, as attorneys-in-fact, with full power of substitution, to execute in the name and on the behalf of each person, individually and in each capacity stated below, and to file, any and all amendments to this registration statement, including any and all post-effective amendments.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated and on February 26, 2026.

Principal Executive Officer

Directors

/s/ FRANK D. LEE

/s/ MARCELO BIGAL

/s/ ABRAHAM CEESAY

Frank D. Lee

Marcelo Bigal

Abraham Ceesay

Chief Executive Officer and Director

/s/ CHRISTOPHER J. CHRISTIE

/s/ MARK FROIMSON

Principal Financial Officer

Christopher J. Christie

Mark Froimson

/s/ SHAWN M. CROSS

/s/ SAMIT HIRAWAT

/s/ MARK KRONENFELD

Shawn M. Cross

Samit Hirawat

Mark Kronenfeld

Chief Financial Officer

/s/ MICHAEL YANG

/s/ ALETHIA YOUNG

Principal Accounting Officer

Michael Yang

Alethia Young

/s/ LAUREN RIKER

/s/ LAURA BREGE

Lauren Riker

Laura Brege

Senior Vice President, Finance

Chair of the Board of Directors

SEC Form S-8 filed by Pacira BioSciences Inc.